2nd Quarter - Termination

TODD STRATEGY GROUP for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
$80,000
Expenses
—
Terminated
Jun 30, 2025

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 19, 2025 $80,000 Replaced
2nd Quarter - Termination (this page) Oct 14, 2025 $80,000 Yes

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies.

LobbyistCovered position, as disclosed
ERIC BERGREN Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
KATHERINE FLEMING COTTON Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
PAUL EDATTEL Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
TED LEHMAN Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
JEFF LUCAS Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
DANIEL M TODD Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid

Contacted: SENATE; HOUSE OF REPRESENTATIVES; White House Office; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 864 (119th)

Health Issues HCR

General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act.

LobbyistCovered position, as disclosed
ERIC BERGREN —
KATHERINE FLEMING COTTON —
PAUL EDATTEL —
TED LEHMAN —
JEFF LUCAS —
DANIEL M TODD —

Contacted: SENATE; White House Office; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1672 (119th), H.R. 946 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.